Immunohistochemical expression of mTOR negatively correlates with PTEN expression in gastric carcinoma

Oncology Letters

Volumn 4, Issue 6, 2012, Pages 1213-1218

  Li, Min ^a   Sun, Huawen ^b   Song, Lujun ^a   Gao, Xiaodong ^a   Chang, Wenju ^a   Qin, Xinyu ^a  

^a FUDAN UNIVERSITY   (China)

^b RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Gastric carcinoma; Immunohistochemistry; mTOR; PTEN

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PARAFFIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER TISSUE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; STOMACH; STOMACH CARCINOMA;

EID: 84867253682     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.930     Document Type: Article

References (42)

1. Washington K: 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol 17: 3077-3079, 2010.
2. Liang S, He L, Zhao X, et al: MicroRNA let-7f inhibits tumor invasion and metastasis by targeting myh9 in human gastric cancer. PloS One 6: e18409, 2011.
3. Roukos DH: Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol 17: 14-17, 2010.
4. Bal N, Kocer NE, Ertorer ME, Canpolat ET and Kayaselcuk F: Maspin, E-selectin, and P-selectin expressions in papillary thyroid carcinomas and their correlation with prognostic parameters. Pathol Res Pract 204: 743-750, 2008.
5. Chen X, Liao J, Lu Y, Duan X and Sun W: Activation of the PI3K Akt pathway mediates bone morphogenetic protein 2-induced invasion of pancreatic cancer cells Panc-1. Pathol Oncol Res 17: 257-261, 2011.
6. Xu Z, Zhang Y, Jiang J, et al: Epidermal growth factor induces HCCR expression via PI3K/Akt/mTOR signaling in PANC-1 pancreatic cancer cells. BMC Cancer 10: 161, 2010.
7. Bhatt AP, Bhende PM, Sin SH, Roy D, Dittmer DP and Damania B: Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood 115: 4455-4463, 2010.
8. Saji M and Ringel MD: The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol 321: 20-28, 2010.
9. Vignot S, Faivre S, Aguirre D and Raymond E: mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16: 525-537, 2005.
10. Mahalingam D, Sankhala K, Mita A, Giles FJ and Mita MM: Targeting the mTOR pathway using deforolimus in cancer therapy. Future Oncol 5: 291-303, 2009.
11. Ching CB and Hansel DE: Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway. Lab Invest 90: 1406-1414, 2010.
12. Carew JS, Kelly KR and Nawrocki ST: Mechanisms of mTOR inhibitor resistance in cancer therapy. Target Oncol 6: 17-27, 2011.
13. Yoshimi A, Goyama S, Watanabe-Okochi N, et al: Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. Blood 117: 3617-3628, 2011.
14. Mireuta M, Darnel A and Pollak M: IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription. Growth Factors 28: 243-255, 2010.
15. Liu C, Wu JL, Xu K, et al: Neuroprotection by baicalein in ischemic brain injury involves PTEN/AKT pathway. J Neurochem 112: 1500-1512, 2010.
16. Hamilton SR and Aaltonen LA (eds): Pathology and Genetics of Tumors of the Digestive System. WHO Press, Geneva, 2000.
17. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene F and Trotti A (eds): AJCC cancer staging manual. 7th edition Springer, New York, 2010.
18. He X, Wei Q, Zhang X, et al: Immunohistochemical expression of CXCR4 in thyroid carcinomas and thyroid benign lesions. Pathol Res Pract 206: 712-715, 2010.
19. Niu HY, Wang JH, Li H and He P: Rapamycin potentiates cytotoxicity by docetaxel possibly through downregulation of Survivin in lung cancer cells. J Exp Clin Canc Res 30: 28, 2011.
20. Chen M, Gu J, Delclos GL, et al: Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis 31: 1387-1391, 2010.
21. Li M, Song L and Qin X: Glycan changes: cancer metastasis and anti-cancer vaccines. J Biosci 35: 665-673, 2010.
22. Sahin F, Kannangai R, Adegbola O, Wang JZ, Su G and Torbenson M: mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 10: 8421-8425, 2004.
23. Schmid K, Bago-Horvath Z, Berger W, et al: Dual inhibition of EGFR and mTOR pathways in small cell lung cancer. Br J Cancer 103: 622-628, 2010.
24. Hirashima K, Baba Y, Watanabe M, et al: Phosphorylated mTOR expression is associated with poor prognosis for patients with esophageal squamous cell carcinoma. Ann Surg Oncol 17: 2486-2493, 2010.
25. Yu G, Wang J, Chen Y, et al: Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of Chinese patients with gastric cancer. Clin Cancer Res 15: 1821-1829, 2009.
26. An J, Jeong H, Lee Y, Woo SU, Seo JH and Kim A: Phosphorylated Akt and phosphorylated mTOR expression in breast invasive carcinomas: analysis of 530 cases. J Breast Cancer 13: 337-348, 2010.
27. Bose S, Chandran S, Mirocha JM and Bose N: The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol 19: 238-245, 2006.
28. Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456, 2008.
29. Marinov M, Ziogas A, Pardo OE, et al: AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. Clin Cancer Res 15: 1277-1287, 2009.
30. Tam KH, Yang ZF, Lau CK, Lam CT, Pang RW and Poon RT: Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma. Cancer Lett 273: 201-209, 2009.
31. Jang KS, Song YS, Jang SH, et al: Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma. Histopathology 56: 229-239, 2010.
32. Andjelkovic T, Bankovic J, Stojsic J, et al: Coalterations of p53 and PTEN tumor suppressor genes in non-small cell lung carcinoma patients. Transl Res 157: 19-28, 2011.
33. Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, et al: PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther 10: 1093-1101, 2011.
34. Mulholland DJ, Tran LM, Li Y, et al: Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19: 792-804, 2011.
35. Hou G, Lu Z, Liu M, Liu H and Xue L: Mutational analysis of the PTEN gene and its effects in esophageal squamous cell carcinoma. Dig Dis Sci 56: 1315-1322, 2011.
36. Langlois MJ, Bergeron S, Bernatchez G, et al: The PTEN phosphatase controls intestinal epithelial cell polarity and barrier function: role in colorectal cancer progression. PloS One 5: e15742, 2010.
37. Li XH, Zheng HC, Takahashi H, Masuda S, Yang XH and Takano Y: PTEN expression and mutation in colorectal carcinomas. Oncol Rep 22: 757-764, 2009.
38. Guo CY, Xu XF, Wu JY and Liu SF: PCR-SSCP-DNA sequencing method in detecting PTEN gene mutation and its significance in human gastric cancer. World J Gastroenterol 14: 3804-3811, 2008.
39. Li M, Song L, Gao X, Chang W and Qin X: Toll-like receptor 4 on islet β cells senses expression changes in high-mobility group box 1 and contributes to the initiation of type 1 diabetes. Exp Mol Med 44: 260-267, 2012.
40. Bakarakos P, Theohari I, Nomikos A, et al: Immunohistochemical study of PTEN and phosphorylated mTOR proteins in familial and sporadic invasive breast carcinomas. Histopathology 56: 876-882, 2010.
41. Cheng ZY, Guo XL, Yang XY, et al: PTEN and rapamycin inhibiting the growth of K562 cells through regulating mTOR signaling pathway. J Exp Clin Cancer Res 27: 87, 2008.
42. Shorning BY, Griffiths D and Clarke AR: Lkb1 and Pten synergise to suppress mTOR-mediated tumorigenesis and epithelial-mesenchymal transition in the mouse bladder. PloS One 6: e16209, 2011.